Bills › 90th General Assembly
SSB 3001
Topics:Business & economyMedicaid
Where it is now
- Done: IntroducedJanuary 9, 2024
- Done: SubcommitteeJanuary 9, 2024
- Done: Senate committeeJanuary 30, 2024
- Skipped: Passes the SenateContinued as SF 2159
- Next: House committee
- Next: Passes the House
- Next: To the Governor
- Next: Signed into law
Became SF 2159 → Its progress continues under the new number. Go to SF 2159 What’s a funnel?
What changed before it passed The bill as introduced compared with the version both chambers passed.
Amendments · 5
2 adopted · 0 failed · 3 never voted on. Newest first.
- H-8294 · filed April 9, 2024 byNever voted onPage 1, by striking lines 14 through 17 and inserting: “c. “Clinical utility” means sufficient medical and scientific evidence indicating that the use of a biomarker test will provide meaningful information that affects…
- S-5124 · filed April 8, 2024 by Sen. Waylon Brown (R)AdoptedPage 1, by striking lines 14 through 17 and inserting: “c. “Clinical utility” means sufficient medical and scientific evidence indicating that the use of a biomarker test will provide meaningful information that affects…April 9, 2024
- S-5123Strike everything · filed April 8, 2024 by Sen. Waylon Brown (R)AdoptedReplaces the whole bill with new text.Amends this SF 2159 to CONFORM to HF 2668April 9, 2024
- H-8050 · filed February 26, 2024 byNever voted onPage 1, after line 7 by inserting: “___. Page 2, by striking lines 16 and 17 and inserting “testing has demonstrated clinical utility, or when the biomarker testing is considered to be a medically necessary service for…
- H-8022 · filed February 19, 2024 byNever voted onPage 1, by striking lines 14 through 17 and inserting: “c. “Clinical utility” means the test result provides information that is used in the formulation of a treatment or monitoring strategy that informs a patient’s… (2 changes)